Physician
Cardiology
Dr. Prakash C. Deedwania, MD
|
|
Give Review
Dr. Prakash C. Deedwania is an expert in the field of Cardiology. He studied medicine at University of Illinois College of Medicine at Chicago. University of Illinois College of Medicine at Chicago is ranked 49/85 in Research/PrimaryCare. He received 1 awards: "Fellow (FACC)". Prakash Deedwania is also published. He has 71 publications published. The lastest publication: "Is Increased Use of Mechanical Circulatory Support Devices Justified?: A Cause for Concern.'
Publications
- Is Increased Use of Mechanical Circulatory Support Devices Justified?: A Cause for Concern.
- The safety and tolerability of beta blockers in Heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified?
- Characteristics and Outcomes of Patients with Advanced Chronic Systolic Heart Failure Receiving Care at the Veterans Affairs vs. Other Hospitals: Insights from the BES...
- Beta-Blocker Use and 30-Day All-Cause Readmission in Medicare Beneficiaries with Systolic Heart Failure.
- Racial differences in mortality in patients with advanced systolic Heart failure: Potential role of right ventricular ejection fraction.
- Resting Heart Rate: Risk Indicator and Emerging Risk Factor in Cardiovascular Disease.
- Calcium-Channel Blockers and Outcomes in Older Patients With Heart Failure and Preserved Ejection Fraction.
- Impact of Atrial fibrillation and heart failure, independent of each other and in combination, on mortality in community-dwelling older adults.
- Spironolactone Use and Higher Hospital Readmission for Medicare Beneficiaries With Heart Failure, Left Ventricular Ejection Fraction <45%, and Estimated Glomerular Fil...
- Statins in chronic kidney Disease: cardiovascular risk and kidney function.
- Medical treatment of hypertension in patients with Heart failure with preserved ejection fraction.
- Digoxin Use and Lower 30-day All-cause Readmission for Medicare Beneficiaries Hospitalized for Heart Failure.
- Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease.
- Prediabetes is not an independent risk factor for incident Heart failure, other cardiovascular events or mortality in older adults: findings from a population-based co...
- Selective and Specific Inhibition of I f with Ivabradine for the Treatment of Coronary Artery Disease or Heart Failure.
- Lipid lowering in patients with treatment-resistant Hypertension: an analysis from the Treating to New Targets (TNT) trial.
- Diabetes, Cardiovascular Disease, and Ethnicity.
- Reduced right ventricular ejection fraction and increased mortality in chronic systolic Heart failure patients receiving beta-blockers: Insights from the BEST trial.
- New Oral Anticoagulants in Elderly Patients with Atrial Fibrillation.
- Ivabradine in Heart failure: hope or hype?
- An update on antithrombotic therapy in Atrial fibrillation: the role of newer and emergent drugs.
- Prediabetes and the risk of diabetes.
- The epidemiology and pathophysiology of Heart failure.
- Evidence-based therapy for Heart failure.
- Atrial fibrillation in heart failure.
- Heart failure: a common and complex clinical syndrome.
- Does Response of RAS Blockade on Serum K+ Levels Influence Its Glycemic-Mitigating Response When Combined With Hydrochlorothiazide?
- Twenty-year trends in cardiovascular risk factors in India and influence of educational status.
- Medical therapy versus myocardial revascularization in chronic Coronary syndrome and stable angina.
- Blood Pressure Control in Diabetes Mellitus: Is Lower Always Better, and How Low Should it Go?
- The anti-ischemic and anti-anginal properties of statins.
- Use of intensive lipid-lowering therapy in patients hospitalized with acute Coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in...
- Use of intensive lipid-lowering therapy in patients hospitalized with acute Coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating ...
- The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus.
- Risk of diabetes and cardiovascular Disease: best to return back to the basics: comment on "Long-term effects of a lifestyle intervention on weight and cardiovasc...
- Usefulness of Heart rate at rest as a predictor of mortality, hospitalization for Heart failure, myocardial infarction, and stroke in patients with stable coronary hea...
- Atrial fibrillation in heart failure: a comprehensive review.
- Beta-adrenergic blockers for chronic Heart failure.
- Getting with the ACC/AHA guidelines for the treatment of chronic angina as a Disease state.
- Lipid levels in patients hospitalized with Coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines.
- Metabolic and antiHypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic Hypertensive patients with the cardiometabolic synd...
- Statins in Heart failure.
- Angiotensin receptor blockers: novel role in high-risk patients.
- Angiotensin receptor blockers and cardiovascular protection: are we ONTARGET?
- Effect of high-dose atorvastatin on hospitalizations for Heart failure: subgroup analysis of the Treating to New Targets (TNT) study.
- Trials and tribulations associated with angina and traditional therapeutic approaches.
- Improving outcomes in post-acute myocardial infarction Heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
- Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technol...
- Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm.
- Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under t...
- The renin angiotensin system as a therapeutic target to prevent diabetes and its complications.
- Diabetes and Hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy.
- Current Treatment Options for the Metabolic Syndrome.
- Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis.
- Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications.
- Diabetes is a vascular Disease: the role of endothelial dysfunction in pathophysiology of cardiovascular Disease in diabetes.
- Treating dyslipidemia in high-risk patients: case reviews and discussion.
- Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome.
- Metabolic syndrome and vascular Disease: is nature or nurture leading the new epidemic of cardiovascular Disease?
- Mechanisms of endothelial dysfunction in the metabolic syndrome.
- The rational use of diuretics in Heart failure.
- The key to unraveling the mystery of mortality in Heart failure: an integrated approach.
- Diabetes and vascular disease: common links in the emerging epidemic of Coronary artery disease.
- Heart failure in the elderly: is beta-blockade the standard of care?
- Is alternate daily dose of atorvastatin effective in treating patients with Hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS).
- Treating Hypertension in patients with diabetes.
- The changing face of Hypertension: is systolic blood pressure the final answer?
- Pharmacotherapy in Congestive heart failure: diuretic resistance and strategies to overcome resistance in patients with Congestive heart failure.
- Clinical significance of cardiovascular dysmetabolic syndrome.
- Randomized Placebo-Controlled Withdrawal Study of Amlodipine in Agina Pectoris.
Schools
Sawai Mansingh Medical College Jaipur
University Of Illinois
Conditions Treated
- Aortic Aneurysm
- Arrhythmias (incl. Atrial Fibrillation)
- Cardiomegaly
- Cardiomyopathy
- View All
Doctors Specialties
- Cardiology
- Pulmonology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Guided Access HMO
- Select Plus HMO
- Select PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Delta Health System
- First Health (Coventry Health Care) PPO
- GEHA
- Blue & Gold HMO
- Covered California - Bronze PPO
- Employer Group HMO
- Health Net PPO
- Individual and Family PPO
- WholeCare Network HMO
- Kaiser Permanente
- Mail Handlers Benefit Plan (MHBP)
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Fellow (FACC)
Education
-
University of Illinois College of Medicine at Chicago -
Icahn School of Medicine at Mount Sinai -
Maimonides Medical Center -
Jawaharlal Nehru Medical College
Helpful Reviews
Similar Doctors
|
|
Dr. Richard G. Kiel, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Albert T. Wilburn, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Harcharn S. Chann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ying-Suen Kong, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ryan A. Berg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles Sohn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yu-Chuan Liu, MD |
|
|
Dr. Phuong-Anh T. Pham, MD |
|
|
Dr. Plamen V. Yosifov, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael L. Krueger, DO
This Doctor is OpenDoctor Recommended.
|